NovaBay Pharmaceuticals I... (NBY)
AMEX: NBY
· Real-Time Price · USD
0.61
0.01 (0.86%)
At close: Aug 15, 2025, 1:12 PM
NovaBay Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 2.31M | 2.44M | 2.4M | 2.63M | 3.73M | 3.25M | 4.61M | 3.12M | 3.64M | 3.83M | 3.04M | 2.63M | 2.64M | 1.84M | 2.13M | 1.81M |
Cost of Revenue | n/a | 807K | 848K | 808K | 837K | 1.91M | 1.42M | 2.3M | 1.19M | 1.89M | 1.45M | 1.5M | 1.11M | 1.21M | 493K | 614K | 455K |
Gross Profit | n/a | 1.5M | 1.59M | 1.59M | 1.79M | 1.81M | 1.84M | 2.31M | 1.94M | 1.75M | 2.38M | 1.55M | 1.52M | 1.43M | 1.35M | 1.52M | 1.35M |
Operating Income | -3.29M | -1.29M | -1.06M | -1.05M | -1.57M | -798K | -1.12M | -1.35M | -1.73M | 2.73M | -457K | -2.15M | -2.38M | -3.19M | -2.29M | -1.86M | -1.52M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -3.33M | -1.32M | -2.22M | -1.58M | -3.09M | -4.11M | -1.76M | -2.04M | -1.74M | -8.21M | -136K | -2.15M | -111K | -158K | -2.29M | -1.86M | -1.52M |
Net Income | 7.67M | -1.21M | -1.21M | -1.58M | -3.21M | -4.11M | -1.76M | -4.03M | -1.74M | -8.21M | -5.79M | -2.15M | -111K | -893K | -2.29M | -1.86M | -1.52M |
Selling & General & Admin | 2.7M | 2.78M | 2.65M | 2.64M | 3.35M | 2.61M | 2.94M | 3.63M | 3.64M | 4.38M | 2.79M | 3.66M | 3.87M | 4.61M | 3.63M | 3.36M | 2.87M |
Research & Development | n/a | 10K | 4K | 9K | 19K | 4K | 11K | 27K | 26K | 66K | 41K | 40K | 28K | 8K | 10K | 21K | 5K |
Other Expenses | 589K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -5K | n/a | n/a | -3K | n/a | n/a | n/a | n/a | 2K |
Operating Expenses | 3.29M | 2.79M | 2.65M | 2.65M | 3.37M | 2.61M | 2.95M | 3.66M | 3.67M | 4.44M | 2.83M | 3.7M | 3.9M | 4.62M | 3.64M | 3.38M | 2.87M |
Interest Expense | n/a | 33K | 138K | 300K | 433K | n/a | n/a | 501K | 5K | n/a | n/a | 3K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 1.01M | 947K | 1.02M | 1.05M | 1.41M | 1.72M | 1.72M | 1.64M | 1.94M | 1.83M | 1.75M | 1.69M | 1.9M | 1.85M | 1.79M | 1.68M |
Cost & Expenses | 3.29M | 3.6M | 3.5M | 3.45M | 4.2M | 4.53M | 4.37M | 5.96M | 4.86M | 6.33M | 4.28M | 5.2M | 5.01M | 5.83M | 4.13M | 3.99M | 3.33M |
Income Tax Expense | n/a | n/a | n/a | n/a | 124K | n/a | n/a | -256K | 5K | -3.49M | -321K | 3K | n/a | 735K | -1K | n/a | n/a |
Shares Outstanding (Basic) | 5.31M | 4.88M | 3.71M | 1.16M | 652.91K | 88.29K | 134.06K | 91K | 75.17K | 54.09K | 45.83K | 43.06K | 40.89K | 36.99K | 36.67K | 34.74K | 34.11K |
Shares Outstanding (Diluted) | 5.42M | 4.88M | 3.71M | 1.16M | 704.91K | 197.06K | 134.06K | 91K | 58.14K | 54.09K | 45.83K | 43.06K | 40.89K | 36.99K | 36.67K | 34.74K | 34.11K |
EPS (Basic) | 1.44 | -0.34 | -0.6 | -1.37 | -4.92 | -46.53 | -13.11 | -40.92 | -23.13 | -151.72 | -126.4 | -50.05 | -2.71 | -24.14 | -62.42 | -53.51 | -44.51 |
EPS (Diluted) | 1.42 | -0.34 | -0.6 | -1.37 | -4.92 | -46.53 | -13.11 | -40.92 | -23.13 | -151.72 | -126.4 | -50.05 | -2.71 | -24.14 | -62.42 | -53.51 | -44.51 |
EBITDA | -3.27M | -1.2M | -979K | -1.04M | -3.08M | -748K | -1.12M | -1.35M | -1.33M | -2.57M | -338K | -2.03M | -2.26M | -3.11M | -2.28M | -1.85M | -1.51M |
EBIT | -3.33M | -1.29M | -1.07M | -1.28M | -2.66M | -798K | -1.12M | -1.23M | -1.34M | -2.69M | -457K | -2.15M | -2.38M | -3.19M | -2.29M | -1.86M | -1.52M |
Depreciation & Amortization | 55K | 95K | 95K | 11K | 12K | 50K | 51K | 51K | 51K | 123K | 119K | 120K | 121K | 87K | 13K | 11K | 9K |